Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 12/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 12/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4829181 | 0.90 | HDAC1 (0.46) | MEN1KMT2AHDAC1HDAC2MAPT | |
| SCHEMBL4836456 | 0.88 | GAA (0.54) | SMN1; SMN2MEN1KMT2AGAAPKM | |
| SCHEMBL4836466 | 0.88 | GAA (0.54) | SMN1; SMN2MEN1KMT2AGAAPKM | |
| SCHEMBL4826902 | 0.84 | PTGDR2 (0.40) | HDAC1HDAC2 | |
| SCHEMBL6432454 | 0.83 | GAA (0.58) | SMN1; SMN2MEN1KMT2AGAAPKM | |
| SCHEMBL4831201 | 0.82 | SMN1; SMN2 (0.51) | SMN1; SMN2MEN1KMT2AGAAPKM | |
| SCHEMBL4831215 | 0.82 | SMN1; SMN2 (0.51) | SMN1; SMN2MEN1KMT2AGAAPKM | |
| SCHEMBL27612943 | 0.82 | SMN1; SMN2 (0.55) | SMN1; SMN2MEN1KMT2AGAAPKM | |
| SCHEMBL1060125 | 0.79 | BTK (0.41) | SMN1; SMN2LMNAKDM4ERAB9ANPC1 | |
| SCHEMBL4829084 | 0.79 | BTK (0.41) | SMN1; SMN2LMNAKDM4ERAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080287438-A1 | Agent for preventing or treating neuropathy | MOMOSE YU | 2008-11-20 | — | — | US | disclosed |
| US-7423159-B2 | Agent for preventing or treating neuropathy | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-09-09 | — | — | US | disclosed |
| US-20060004069-A1 | Agent for preventing or treating neuropathy | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-01-05 | — | — | US | disclosed |
| EP-1556032-A1 | AGENT FOR PREVENTING OR TREATING NEUROPATHY | Takeda Pharmaceutical Company Limited (JP) | 2005-07-27 | — | — | EP | disclosed |
| WO-2004039365-A1 | AGENT FOR PREVENTING OR TREATING NEUROPATHY | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-05-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004069-A1 | Agent for preventing or treating neuropathy | NR2C2, NR0B2, NR2E1 | SMN1; SMN2 75/4885MEN1 3516/4885KMT2A 1653/4885 |
| US-20080287438-A1 | Agent for preventing or treating neuropathy | NR2C2, NR0B2, NR2E1 | SMN1; SMN2 75/4885MEN1 3516/4885KMT2A 1653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.